Zobrazeno 1 - 10
of 276
pro vyhledávání: '"Prahlad V"'
Autor:
Xue Lu, Yaowu He, Rebecca L. Johnston, Devathri Nanayakarra, Sivanandhini Sankarasubramanian, J. Alejandro Lopez, Michael Friedlander, Murugan Kalimutho, John D. Hooper, Prahlad V. Raninga, Kum Kum Khanna
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-17 (2022)
Abstract Background High-grade serous ovarian carcinomas (HGSCs) are a heterogeneous subtype of epithelial ovarian cancers and include serous cancers arising in the fallopian tube and peritoneum. These cancers are now subdivided into homologous recom
Externí odkaz:
https://doaj.org/article/fc0340ce6f43428181428979968908a9
Autor:
Jun Hui Sze, Prahlad V. Raninga, Kyohei Nakamura, Mika Casey, Kum Kum Khanna, Susan J. Berners-Price, Giovanna Di Trapani, Kathryn F. Tonissen
Publikováno v:
Redox Biology, Vol 28, Iss , Pp - (2020)
Multiple myeloma (MM), the second most common haematological malignancy, is a clonal plasma B-cell neoplasm that forms within the bone marrow. Despite recent advancements in treatment, MM remains an incurable disease. Auranofin, a linear gold(I) phos
Externí odkaz:
https://doaj.org/article/8f24779605f34d5986f2b92b03fc7460
Publikováno v:
Redox Biology, Vol 8, Iss C, Pp 175-185 (2016)
Multiple myeloma (MM) is characterized by an accumulation of abnormal clonal plasma cells in the bone marrow. Despite recent advancements in anti-myeloma therapies, MM remains an incurable disease. Antioxidant molecules are upregulated in many cancer
Externí odkaz:
https://doaj.org/article/89c2721bec4540299f46f058504194c7
Publikováno v:
Antioxidants, Vol 9, Iss 3, p 207 (2020)
Chronic myeloid leukaemia (CML) is currently treated with inhibitors of the CML specific oncoprotein, bcr-abl. While this strategy is initially successful, drug resistance can become a problem. Therefore, new targets need to be identified to ensure t
Externí odkaz:
https://doaj.org/article/6524ea5e82f34548a364c006c51dae5e
Autor:
Raninga, Prahlad V., He, Yaowu, Datta, Keshava K., Lu, Xue, Maheshwari, Uma R., Venkat, Pooja, Mayoh, Chelsea, Gowda, Harsha, Kalimutho, Murugan, Hooper, John D., Khanna, Kum Kum
Publikováno v:
In Molecular Therapy 1 March 2023 31(3):729-743
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Lu, Xue, He, Yaowu, Johnston, Rebecca L., Nanayakarra, Devathri, Sankarasubramanian, Sivanandhini, Lopez, J. Alejandro, Friedlander, Michael, Kalimutho, Murugan, Hooper, John D., Raninga, Prahlad V., Khanna, Kum Kum
Additional file 2: Supplementary figs. S1 – S5.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23e1e7065d0bcac590969f4f344be101
Autor:
G. N. Nagaharish, Abdulrajak Buradi, Prahlad V. Deshpande, Nitesh Basavaraj Hallad, A. Madhusudhan, Bhaskor Jyoti Bora
Publikováno v:
Lecture Notes in Mechanical Engineering ISBN: 9789811969690
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e62b0928847f6342bf5206b4d24f51b5
https://doi.org/10.1007/978-981-19-6970-6_2
https://doi.org/10.1007/978-981-19-6970-6_2
Autor:
Prahlad V. Raninga, Yaowu He, Keshava K. Datta, Xue Lu, Uma R. Maheshwari, Pooja Venkat, Chelsea Mayoh, Harsha Gowda, Murugan Kalimutho, John D. Hooper, Kum Kum Khanna
Approximately 50%–55% of high-grade serous ovarian carcinoma (HGSOC) patients have MYC oncogenic pathway activation. Because MYC is not directly targetable, we have analyzed molecular pathways enriched in MYC-high HGSOC tumors to identify potential
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a3aadf54d810b0c29fe4490134619a3
Autor:
Lu, Xue, He, Yaowu, Johnston, Rebecca L., Nanayakarra, Devathri, Sankarasubramanian, Sivanandhini, Lopez, J. Alejandro, Friedlander, Michael, Kalimutho, Murugan, Hooper, John D., Raninga, Prahlad V., Khanna, Kum Kum
Additional file 1: Supplementary methods.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::278300205805eb4c3ef839fb3287c5f5